Update of the SEIOMM clinical guideline of osteoporosis: abaloparatide

Osteoporosis is a highly prevalent condition. SEIOMM has published guidelines for managing these patients in 2022. The recent introduction of a new drug in Europe, abaloparatide, makes it advisable to consider its role among therapeutic options.

This article summarizes the existing information on the efficacy and safety of abaloparatide and it updates the therapeutic algorithms proposed in the guidelines.

Abaloparatide is an osteoanabolic drug with efficacy and safety similar to teriparatide. It represents a new option for treating patients with severe osteoporosis and a very high risk of fracture.

Published by Revista clinica espanola, 2025. The guideline itself is at the source linked here.

doi.org/10.1016/j.rceng.2025.502338